CoChat

Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Human growth hormone (GH) is widely used as an antiaging therapy, although its use for this purpose has not been approved by the U.S. Food and Drug Administration and its distribution as an antiaging agent is illegal in the United States. PURPOSE: To evaluate the safety and efficacy of GH therapy in the healthy elderly. DATA SOURCES: The authors searched MEDLINE and EMBASE databases for English-language studies published through 21 November 2005 by using such terms as growth hormone and aging. STUDY SELECTION: The authors included randomized, controlled trials that compared GH therapy with no GH therapy or GH and lifestyle interventions (exercise with or without diet) with lifestyle interventions alone. Included trials provided GH for 2 weeks or more to community-dwelling participants with a mean age of 50 years or more and a body mass index of 35 kg/m2 or less. The authors excluded studies that evaluated GH as treatment for a specific illness. DATA EXTRACTION: Two authors independently reviewed articles and abstracted data. DATA SYNTHESIS: 31 articles describing 18 unique study populations met the inclusion criteria. A total of 220 participants who received GH (107 person-years) completed their respective studies. Study participants were elderly (mean age, 69 years [SD, 6]) and overweight (mean body mass index, 28 kg/m2 [SD, 2]). Initial daily GH dose (mean, 14 microg per kg of body weight [SD, 7]) and treatment duration (mean, 27 weeks [SD, 16]) varied. In participants treated with GH compared with those not treated with GH, overall fat mass decreased (change in fat mass, -2.1 kg [95% CI, -2.8 to -1.35] and overall lean body mass increased (change in lean body mass, 2.1 kg [CI, 1.3 to 2.9]) (P < 0.001), and their weight did not change significantly (change in weight, 0.1 kg [CI, -0.7 to 0.8]; P = 0.87). Total cholesterol levels decreased (change in cholesterol, -0.29 mmol/L [-11.21 mg/dL]; P = 0.006), although not significantly after adjustment for body composition changes. Other outcomes, including bone density and other serum lipid levels, did not change. Persons treated with GH were significantly more likely to experience soft tissue edema, arthralgias, carpal tunnel syndrome, and gynecomastia and were somewhat more likely to experience the onset of diabetes mellitus and impaired fasting glucose. LIMITATIONS: Some important outcomes were infrequently or heterogeneously measured and could not be synthesized. Most included studies had small sample sizes. CONCLUSIONS: The literature published on randomized, controlled trials evaluating GH therapy in the healthy elderly is limited but suggests that it is associated with small changes in body composition and increased rates of adverse events. On the basis of this evidence, GH cannot be recommended as an antiaging therapy.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-146-2-200701160-00005

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 75 references

Research works printed but not linked: 24

  1. Lamberts SW, 2000, Horm Res, 53, 42
  2. Hoffman AR, 1999, J Endocrinol Invest, 22, 4
  3. Savine R, 1999, J Endocrinol Invest, 22, 142
  4. Savine R, 2000, Horm Res, 53, 37
  5. Biller BM, 2000, J Clin Endocrinol Metab, 85, 970
  6. Lyle WG, 2002, Plast Reconstr Surg, 110, 1585
  7. 10.1210/jcem.87.2.8206 · doi:10.1210/jcem.87.2.8206 · Paper page
  8. 10.1210/jcem.86.8.7773 · DOI · Paper page
  9. Johannsson G, 1997, J Clin Endocrinol Metab, 82, 727
  10. Holloway L, 1994, J Clin Endocrinol Metab, 79, 470
  11. Thompson JL, 1998, J Clin Endocrinol Metab, 83, 1477
  12. Taaffe DR, 1996, J Clin Endocrinol Metab, 81, 421
  13. Yarasheski KE, 1995, Am J Physiol, 268, 268
  14. Taaffe DR, 1994, J Clin Endocrinol Metab, 79, 1361
  15. Viikari J, 1998, Duodecim, 114, 867
  16. Bierich JR, 1991, Z Gerontol, 24, 337
  17. Kozakowski J, 1998, Pol Arch Med Wewn, 100, 306
  18. Kann P, 1996, Med Klin (Munich), 91, 46
  19. Jørgensen JO, 1999, J Endocrinol Invest, 22, 150
  20. 10.1210/jcem.87.6.8542 · doi:10.1210/jcem.87.6.8542 · Paper page
  21. Bengtsson BA, 1993, J Clin Endocrinol Metab, 76, 309
  22. 10.1210/jcem.87.5.8454 · doi:10.1210/jcem.87.5.8454 · Paper page
  23. Johannsson G, 1996, Endocrinol Metab Clin North Am, 3, 3
  24. 10.1210/jcem.83.11.5223 · DOI · Paper page

Cited by

See all 370

Metadata

Authors
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R.
Affiliations
VA Palo Alto Health Care System (US)
Venue
Annals of Internal Medicine
Published
2007-01-16
Volume
146
Issue
2
Pages
104-115
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2044351326
Cited by
370
References
74
Citations by year
2026: 12 · 2025: 13 · 2024: 10 · 2023: 12 · 2022: 16 · 2021: 22 · 2020: 9 · 2019: 24 · 2018: 18 · 2017: 19 · 2016: 17 · 2015: 10 · 2014: 16 · 2013: 18 · 2012: 19
FWCI
5.07
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Agency for Healthcare Research and Quality (HS000028-19)
  • Genentech
  • National Institute on Aging (AG 17253, P30AG017253)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
growth hormone therapy, anti-aging therapy, healthy older adults, overweight adults, body composition, fat mass, lean body mass, cholesterol, bone mineral density, soft tissue edema, adverse effects, lifestyle intervention, diet and exercise, drug safety and efficacy, osteoporosis, osteoarthritis, avascular necrosis, cancer risk, cardiovascular risk
MeSH terms
Aged, Aging, Blood Glucose, Body Composition, Humans, Life Style, Lipids, Recombinant Proteins, Exercise, Bone Density, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. https://app.cochat.ai/papers/10.7326/0003-4819-146-2-200701160-00005
The paper
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007). Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-2-200701160-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.